LME analysis of SCR and PSR during trace fear acquisition
| CS presentation | Trace interval | US time point | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Fear acquisition SCR | F value | df | p-value | F value | df | p-value | F value | df | p-value |
| Drug (doxycycline/placebo) | 8.99 | 1, 1002.7 | 0.003* | 0.43 | 1, 324.8 | 0.51 | 2.74 | 1, 266.2 | 0.1 |
| Condition (CS+/CS−) | 22.27 | 1, 3727.3 | >0.001* | 42.9 | 1, 3726 | >0.001* | 78.6 | 1, 3731.9 | >0.001* |
| Trial number | 16.97 | 1, 3726.2 | >0.001* | 11.2 | 1, 3725.1 | >0.001* | 27.2 | 1, 3731.2 | >0.001* |
| Drug × Condition | 0.61 | 1, 3727.3 | 0.435 | 3.68 | 1, 3726 | 0.06 | 3.74 | 1, 3731.9 | 0.05 |
| Drug × Trial | 11.79 | 1, 3726.2 | >0.001* | 7.23 | 1, 3725.1 | 0.007* | 3.16 | 1, 3731.2 | 0.08 |
| Condition × Trial | 2.09 | 1, 3728.1 | 0.149 | 1.24 | 1, 3726.5 | 0.27 | 2.9 | 1, 3732.1 | 0.09 |
| Drug × Condition × Trial | 0.45 | 1, 3728.1 | 0.501 | 0.36 | 1, 3726.5 | 0.55 | 2.12 | 1, 3732.1 | 0.15 |
| Fear acquisition PSR | F value | df | p-value | ||||||
| Drug (doxycycline/placebo) | 0.2 | 1, 484.9 | 0.655 | ||||||
| Condition (CS+/CS−) | 53.5 | 1, 3739.4 | >0.001* | ||||||
| Trial number | 0.75 | 1, 3738 | 0.387 | ||||||
| Drug × Condition | 0.63 | 1, 3739.4 | 0.429 | ||||||
| Drug × Trial | 0.06 | 1, 3738 | 0.803 | ||||||
| Condition × Trial | 3.04 | 1, 3739.8 | 0.081 | ||||||
| Drug × Condition × Trial | 1.56 | 1, 3739.8 | 0.212 | ||||||
Models are estimated with lme4, lmer(data ∼ (1|subject) + group*condition*trial), significant (p < 0.05) effects are marked with a * after Holm–Bonferroni correction, for robustness analysis, see Extended Data Table 3-1.